AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Increasing degradation of Hypoxia-Inducible Factors impairs cancer stem cell proliferation

Summary: This technology describes a method for treating ID2 protein-related diseases through increased degradation of Hypoxia-Inducible Factors (HIFs).

Technology Benefits: Mechanism-backed treatment of ID2 protein-related diseasesApplicable to multiple types of hypoxia-related cancersProvides multiple drug targets for increasing degradation of HIFs, reducing risk of resistance

Technology Application: Treatment and prevention of glioblastoma and other cancersTreatment and prevention of other ID2 protein-related diseasesResearch tool for developing additional targeted therapeutics

Detailed Technology Description: None

*Abstract: None

*Inquiry: Ron KatzColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR: CU16166

*Principal Investigator

*Publications: Lee S, Frattini V, Bansal M, Castano A, Sherman D, Hutchinson K, Califano A, Liu G, Cordozo T, Iavarone A, Lasorella A. “An ID2-dependent mechanism for VHL inactivation in cancer” Nature. 2016 Jan 14;529(7585):172-177.Tech Ventures Reference:IR CU16166Licensing Contact: Ron Katz

Country/Region: USA

For more information, please click Here